NDD CKD
Advertisement
How does early vs delayed treatment with long-acting ESAs affect renal and cardiovascular outcomes in patients with NDD-CKD?
The FDA has granted Fast Track designation DISC-0974 for the treatment of anemia in patients with NDD-CKD.
Researchers led by Ting Chen, PhD conducted a systematic review and meta-analysis to examine the efficacy and safety of ...
Patients with anemia due to chronic kidney disease (CKD) are commonly treated with erythropoiesis-stimulating agents ...
The prevalence of chronic kidney disease (CKD) is greater in individuals ≥65 years of age compared with those 45 to 64 ...
In phase 3 studies examining the efficacy of roxadustat for the treatment of anemia in patients with chronic kidney ...
In the OLYMPUS trial, researchers examined the efficacy of roxadustat for the treatment of anemia in patients with ...
Patients requiring red blood cell transfusions may experience reactions leading to allo-sensitization, or rarely ...
Anemia is a common comorbidity in patients with chronic kidney disease (CKD); however, there are few data available on ...
Analyses of pooled results of phase 3 studies of roxadustat for the treatment of anemia in patients with chronic kidney ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.